Illumina Announces Appointments of Elizabeth Brady as Vice President, Global Supply Chain, and Emily Winn-Deen as Vice President, Diagnostics Development

Illumina, Inc. (NASDAQ:ILMN) today announced the appointments of Elizabeth Brady as vice president, Global Supply Chain, and Emily S. Winn-Deen, Ph.D., as vice president, Diagnostics Development.

Ms. Brady will be responsible for Illumina’s global sourcing, planning, logistics and distribution operations, reporting to William Bonnar, senior vice president, Operations. "Elizabeth has an outstanding background as a senior leader with extensive global experience in supply chain management spanning the electronics and healthcare industries,” said Mr. Bonnar. "At Illumina, she will play a critical role in building a world-class supply chain operation that will be a key element in realizing our growth objectives.”

Prior to joining Illumina, Ms. Brady served as vice president, Global Supply Chain, Cardiac Rhythm Management Division of Boston Scientific Corporation, where she built a supply chain organization that helped successfully launch new products, reduce obsolete inventory, implement life cycle management and reduce planning cycle time. Previously, she served as vice president, Supply Chain, at Tellabs Operations, Inc., a maker of telecom infrastructure equipment. She also held supply chain leadership positions in the U.S. and Ireland with 3Com Corporation. Ms. Brady holds a B.S. in Business Analysis and Business Economics from Indiana University, Bloomington.

Dr. Winn-Deen will be responsible for the development of diagnostics products at Illumina, reporting to Gregory Heath, Ph.D., senior vice president and general manager, Diagnostics. "Emily brings an impressive track record of more than 20 years of successful leadership in the life sciences and diagnostics fields, much of it focused on novel biomarkers and product development for emerging markets,” said Dr. Heath. "As head of development, she will play a crucial role in building Illumina’s diagnostics capability and paving the way for our future leadership in this critical area.”

Prior to joining Illumina, Dr. Winn-Deen served as president of Rx Dx Advisors, a consulting practice focused on evaluating market trends and new technology, corporate partnering, business and product development, and regulatory compliance. Previously, at Cepheid, she held vice president positions in Genetics and Oncology R&D, and in Strategic Development and Business Planning. She has served in senior R&D positions at a range of diagnostics and pharmaceutical companies, including Roche Molecular Systems, Applera Corporation, Oncor and Bayer Diagnostics. Dr. Winn-Deen holds a B.A. in chemistry from Lehigh University and a Ph.D. in chemistry from Boston University.

About Ms. Brady’s and Dr. Winn-Deen’s Compensation

Illumina granted an option to purchase 120,000 shares of Illumina's common stock to Ms. Brady and an option to purchase 112,000 shares of Illumina’s common stock to Dr. Winn-Deen, as part of their inducement to join the company. The options were granted by Illumina’s Compensation Committee pursuant to NASDAQ Marketplace Rule 5635(c)(4) and under Illumina's New Hire Stock and Incentive Plan, which was approved by Illumina's Board of Directors on January 29, 2008. These options have the following terms: an exercise price equal to the closing fair market value of Illumina's common stock on the grant date, a ten-year term, and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter. The grant date for the option to Ms. Brady is May 3, 2010. The grant date for the option to Dr. Winn-Deen is April 26, 2010.

For more information about careers at Illumina, please visit www.illumina.com/careers.

About Illumina

Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.